



**Listing of Claims:**

1. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier substance and a compound of the formula (I) or (Ia), and/or a pharmaceutically acceptable acid addition salt thereof,



(I)



(Ia)

in which the substituents have the following significance:

R<sub>1</sub>: C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyl, where alkyl is C<sub>1</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyl, where alkenyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyl, where alkinyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>7</sub>-C<sub>16</sub>-arylalkyl where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl;

R<sub>2</sub>: C<sub>4</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyl, where alkyl is C<sub>1</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyl, where alkenyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyl, where alkinyl is C<sub>2</sub>-C<sub>6</sub>; C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>, C<sub>13</sub>, C<sub>14</sub>, C<sub>15</sub>, or C<sub>16</sub>-arylalkyl, where

aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>, C<sub>10</sub>, C<sub>11</sub>, C<sub>12</sub>, C<sub>13</sub>, C<sub>14</sub>, C<sub>15</sub> or C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>6</sub>-alkinoyl; and C<sub>9</sub>-C<sub>16</sub>-arylalkinoyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinoyl is C<sub>3</sub>-C<sub>6</sub>-alkinoyl;

R<sub>3</sub>: hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; alkoxyalkyl, where alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkoxy and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; CO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>-alkyl); CO<sub>2</sub>H; CH<sub>2</sub>OH;

R<sub>4</sub>: hydrogen; hydroxy; C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is C<sub>1</sub>-C<sub>4</sub> alkyloxy and alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyloxy; C<sub>2</sub>-C<sub>6</sub>-alkinyloxy; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyloxy, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyloxy where alkinyl is C<sub>2</sub>-C<sub>6</sub> alkinyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>1</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>3</sub>-C<sub>6</sub>-alkenoyloxy; C<sub>3</sub>-C<sub>6</sub>-alkinoyloxy; C<sub>7</sub>-C<sub>16</sub>-arylalkanoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkanoyloxy is C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>9</sub>-C<sub>16</sub>-arylalkenoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenoyloxy is C<sub>3</sub>-C<sub>6</sub>-alkenoyloxy; C<sub>9</sub>-C<sub>16</sub>-arylalkinoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinoyloxy is C<sub>3</sub>-C<sub>6</sub>-alkinoyloxy;

R<sub>5</sub>: hydrogen; hydroxy; C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is C<sub>1</sub>-C<sub>4</sub> alkyloxy and alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyloxy; C<sub>2</sub>-C<sub>6</sub>-alkinyloxy; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyloxy, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyloxy, where alkinyl is C<sub>2</sub>-C<sub>6</sub> alkinyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub> alkinyl; C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>7</sub>-C<sub>16</sub>-arylalkanoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkanoyloxy is C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy;

X is oxygen;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkinyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-alkoxy, CO<sub>2</sub>H, CONH<sub>2</sub>, CO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), CONH(C<sub>1</sub>-C<sub>3</sub>-alkyl), CON(C<sub>1</sub>-C<sub>3</sub>-alkyl)<sub>2</sub>, CO(C<sub>1</sub>-C<sub>3</sub>-alkyl); amino; (C<sub>1</sub>-C<sub>3</sub>-monoalkyl)amino, (C<sub>1</sub>-C<sub>3</sub>-dialkyl)amino; C<sub>5</sub>-C<sub>6</sub>-cycloalkylamino, (C<sub>1</sub>-C<sub>3</sub>-alkanoyl)amido, SH, SO<sub>3</sub>H, SO<sub>3</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>-alkyl), SO(C<sub>1</sub>-C<sub>3</sub>-alkyl), C<sub>1</sub>-C<sub>3</sub>-alkylthio or C<sub>1</sub>-C<sub>3</sub>-alkanoylthio,


wherein -(cyclical saturated group) is either preferably C<sub>3</sub>-C<sub>10</sub>-cycloalkyl or a heterocyclic group with 2 to 9 carbon atoms, containing further one or more heteroatoms,

**with the exception of compounds** where  $R_1$  is methyl,  $R_2$  is  $C_4$ - $C_6$ -alkyl,  $R_3$  is hydrogen or methyl,  $R_4$  is hydroxy or methoxy and  $R_5$  is hydroxy, methoxy or an oxygen atom bound to the carbon atom in the 5<sup>th</sup> position,


**with the further exception of compounds** where  $R_1$  is cyclopropylmethyl and  $XR_2$  is benzyloxy, when  $R_4$  is hydrogen or benzyloxy and  $R_5$  is an oxygen atom bound to the carbon atom in the 5<sup>th</sup> position; and

**with the further exception of compounds** where  $R_1$  is cyclopropylmethyl and  $XR_2$  is benzyloxy, when  $R_4$  is hydrogen, hydroxy or benzyloxy and  $R_5$  is hydroxy or methoxy.

2. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier substance and a compound of the formula (IA) or (IAa), and/or a pharmaceutically acceptable acid addition salt thereof,



(IA)



(IAa)

where the substituents have the following significance:

$R_1$ :  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_2$ - $C_6$ -alkinyl;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyl, where alkyl is  $C_1$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyl, where alkenyl is  $C_2$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyl, where alkinyl is  $C_2$ - $C_6$ ;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl;  $C_8$ - $C_{16}$ -arylalkinyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_2$ - $C_8$ -alkinyl;

wherein the two substituents  $R_1$  can be the same or different;

$R_2$ :  $C_2$ -alkyl,  $C_3$ -alkyl,  $C_4$ -alkyl,  $C_5$ -alkyl or  $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_2$ - $C_6$ -alkinyl;  $C_3$ - $C_{16}$ -(cyclical saturated group)alkyl, where alkyl is  $C_1$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkenyl, where alkenyl is  $C_2$ - $C_6$ ;  $C_4$ - $C_{16}$ -(cyclical saturated group)alkinyl, where alkinyl is  $C_2$ - $C_6$ ;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl;  $C_8$ - $C_{16}$ -arylalkinyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinyl is  $C_2$ - $C_6$ -alkinyl;  $C_3$ - $C_6$ -alkenoyl;  $C_3$ - $C_6$ -alkinoyl;  $C_9$ - $C_{16}$ -arylalkenoyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenoyl is  $C_3$ - $C_6$ -alkenoyl;  $C_9$ - $C_{16}$ -arylalkinoyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkinoyl is  $C_3$ - $C_6$ -alkinoyl;

$R_3$ : hydrogen,  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl; alkoxyalkyl, where alkoxy is  $C_1$ - $C_6$ -alkoxy and alkyl is  $C_1$ - $C_6$ -alkyl;  $CO_2(C_1-C_6\text{-alkyl})$ ;  $CO_2H$ ;  $CH_2OH$ ;

R<sub>4</sub>: hydrogen; hydroxy; C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is C<sub>1</sub>-C<sub>4</sub> alkyloxy and alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyloxy; C<sub>2</sub>-C<sub>6</sub>-alkinyloxy; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyloxy, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyloxy where alkinyl is C<sub>2</sub>-C<sub>6</sub> alkinyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>3</sub>-C<sub>6</sub>-alkenoyloxy; C<sub>3</sub>-C<sub>6</sub>-alkinoyloxy; C<sub>8</sub>-C<sub>16</sub>-arylalkanoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkanoyloxy is C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>9</sub>-C<sub>16</sub>-arylalkenoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenoyloxy is C<sub>3</sub>-C<sub>6</sub>-alkenoyloxy; C<sub>9</sub>-C<sub>16</sub>-arylalkinoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinoyloxy is C<sub>3</sub>-C<sub>6</sub>-alkinoyloxy;

R<sub>5</sub>: hydrogen; hydroxy; C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>10</sub>-alkyloxyalkoxy, where alkyloxy is C<sub>1</sub>-C<sub>4</sub> alkyloxy and alkoxy is C<sub>1</sub>-C<sub>6</sub>-alkyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyloxy; C<sub>2</sub>-C<sub>6</sub>-alkinyloxy; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyloxy, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyloxy, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyloxy, where alkinyl is C<sub>2</sub>-C<sub>6</sub> alkinyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy; C<sub>7</sub>-C<sub>16</sub>-arylalkanoyloxy, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkanoyloxy is C<sub>2</sub>-C<sub>6</sub>-alkanoyloxy;

X is oxygen;

$Y^-$  is  $I^-$ ,  $Br^-$ ,  $Cl^-$ ,  $OH^-$  or another pharmacologically acceptable counterion;

wherein a single or double bond can be present between the carbon atoms of numbers 7 and 8,

wherein alkyl, alkenyl and alkinyl can each be branched or unbranched, aryl can be unsubstituted or mono-, di- or trisubstituted, independently in each case, with hydroxy, halogen, nitro, cyano, thiocyanato, trifluoromethyl,  $C_1$ - $C_3$ -alkyl,  $C_1$ - $C_3$ -alkoxy,  $CO_2H$ ,  $CONH_2$ ,  $CO_2(C_1$ - $C_3$ -alkyl),  $CONH(C_1$ - $C_3$ -alkyl),  $CON(C_1$ - $C_3$ -alkyl)<sub>2</sub>,  $CO(C_1$ - $C_3$ -alkyl); amino; ( $C_1$ - $C_3$ -monoalkyl)amino, ( $C_1$ - $C_3$ -dialkyl)amino;  $C_5$ - $C_6$ -cycloalkylamino, ( $C_1$ - $C_3$ -alkanoyl)amido,  $SH$ ,  $SO_3H$ ,  $SO_3(C_1$ - $C_3$ -alkyl),  $SO_2(C_1$ - $C_3$ -alkyl),  $SO(C_1$ - $C_3$ -alkyl),  $C_1$ - $C_3$ -alkylthio or  $C_1$ - $C_3$ -alkanoylthio, wherein -(cyclical saturated group) is either preferably  $C_3$ - $C_{10}$ -cycloalkyl or a heterocyclical group with 2 to 9 carbon atoms, containing furthermore one or more heteroatoms.

3. (Previously Presented) A composition of claim 1 or 2, wherein for the compound of formula (I) or (IA),  $R_1$  is  $C_1$ - $C_6$ -alkyl;  $C_2$ - $C_6$ -alkenyl;  $C_4$ - $C_{16}$ -cycloalkylalkyl, where cycloalkyl is  $C_3$ - $C_{10}$  cycloalkyl and alkyl is  $C_1$ - $C_6$  alkyl;  $C_7$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $R_2$  is  $C_8$ - $C_{16}$ -arylalkyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkyl is  $C_1$ - $C_6$ -alkyl;  $C_8$ -arylalkenyl or  $C_{10}$ - $C_{16}$ -arylalkenyl, where aryl is  $C_6$ - $C_{10}$ -aryl and alkenyl is  $C_2$ - $C_6$ -alkenyl;  $R_3$  is hydrogen or methyl;  $R_4$  is hydroxy, methoxy or acetoxy.

4. (Previously Presented) A composition of claim 2, wherein for the compound of formula (IA), R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>4</sub>-C<sub>16</sub>-cycloalkylalkyl, where cycloalkyl is C<sub>3</sub>-C<sub>10</sub> cycloalkyl and alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; R<sub>2</sub> is C<sub>2</sub>-C<sub>6</sub>-alkyl or C<sub>2</sub>-C<sub>6</sub>-alkenyl, R<sub>3</sub> is hydrogen or methyl; R<sub>4</sub> is hydroxy, methoxy or acetoxy.

5. (Previously Presented) A composition of claim 1 or 2, wherein the compound is selected from:

17-allyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-allyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclobutylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ ,17-dimethyl-14 $\beta$ -[(3-phenylpropyl)oxy)morphinan-6-one, 4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ ,17-dimethyl-14 $\beta$ -[(3-phenylpropyl)oxy)morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-

phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-propyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-tetrahydrofurfuryl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-(2-phenylethyl)-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5 $\alpha$ -epoxy-3-methoxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-ethyl-4,5 $\alpha$ -epoxy-3-hydroxy-5 $\beta$ -methyl-14 $\beta$ -(3-phenylpropyloxy)morphinan-6-one, 17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -[(2-methylbenzyl)oxy]morphinan-6-one, 14 $\beta$ -butoxy-17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxymorphinan-6-one, 4,5 $\alpha$ -epoxy-5 $\beta$ ,17-dimethyl-14 $\beta$ -[(3-phenylpropyl)oxy]-3-[(prop-2-inyl)oxy]morphinan-6-one, 4,5 $\alpha$ -epoxy-17-ethyl-3-methoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 $\alpha$ -epoxy-17-ethyl-3-hydroxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -[(3-methylbutyl)oxy]-17-propylmorphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-17-methyl-14-[(3-phenylpropyl)oxy]-morphinan-6-one, 4-hydroxy-3-methoxy-17-methyl-14 $\beta$ -[(2-naphthylmethyl)oxy]morphinan-6-one, 3,4-dimethoxy-17-methyl-

14 $\beta$ -[(2-naphthylmethyl)oxy]morphinan-6-one, 4-hydroxy-3-methoxy-5 $\beta$ ,17-dimethyl-14 $\beta$ -[(3-phenylpropyl)oxy]-morphinan-6-one, 3,4-dimethoxy-5 $\beta$ ,17-dimethyl-14 $\beta$ -[(3-phenylpropyl)oxy]-morphinan-6-one, 4,5 $\alpha$ -epoxy-3-hydroxy-17,17-dimethyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]morphinanum-iodide, (17S)-4,5 $\alpha$ -epoxy-17-ethyl-3-hydroxy-17-methyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]morphinanum-iodide, (17R)-4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]-17-[(2(R,S)-tetrahydrofuran-2-yl)methyl]morphinanum-iodide, 5 $\beta$ -benzyl-14 $\beta$ -(butyloxy)-4,5-epoxy-3-hydroxy-17,17-dimethyl-6-oxomorphinanum-iodide, (17S)-17-allyl-5 $\beta$ -benzyl-14 $\beta$ -butoxy-4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-6-oxomorphinanum-iodide, 14 $\beta$ -butoxy-4,5 $\alpha$ -epoxy-3-hydroxy-17,17-dimethyl-6-oxomorphinanum-iodide, (17R)-17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]morphinanum-iodide, (17R)-17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-methoxy-17-methyl-6-oxo-14 $\beta$ -[(3-phenylpropyl)oxy]morphinanum-iodide, (17R)-17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-6-oxo-14 $\beta$ -[(2-phenylbenzyl)oxy]morphinanum-iodide, 4,5 $\alpha$ -epoxy-3-methoxy-17-methyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 $\alpha$ -epoxy-3-methoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 4,5 $\alpha$ -epoxy-17-methyl-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4,5 $\alpha$ -epoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4-hydroxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 17-(cyclopropylmethyl)-4-methoxy-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, 4-(n-butyloxy)-17-(cyclopropylmethyl)-14 $\beta$ -[(3-phenylpropyl)oxy]morphinan-6-one, and a pharmaceutically acceptable salt thereof.

Claim 6. (Cancelled)

Claim 7. (Cancelled).

8. (Previously Presented) A method of treating pain, comprising the step of administering to a patient in need thereof an effective amount of the composition of claim 1 or 2.

9. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R<sub>5</sub> is OH or alkyloxy.

10. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R<sub>3</sub> is hydrogen, alkyl or aralkyl.

11. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R<sub>4</sub> is OH, alkyloxy, alkenyloxy or alkinyloxy.

12. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, a single bond is present between carbon atom numbers 7 and 8.

13. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R<sub>2</sub> is alkyl or aralkyl.

14. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R<sub>1</sub> is alkyl, (cyclical saturated group)alkyl, aralkyl or alkenyl.

15. (Previously Presented) A composition according to Claim 1 or 2, wherein in the compound, R<sub>1</sub> is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-alkinyl; C<sub>3</sub>-C<sub>16</sub>-(cyclical saturated group)alkyl, where alkyl is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkenyl, where alkenyl is C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>4</sub>-C<sub>16</sub>-(cyclical saturated group)alkinyl, where alkinyl is C<sub>2</sub>-C<sub>6</sub> alkinyl; C<sub>7</sub>-C<sub>16</sub>-arylalkyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkyl is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>8</sub>-C<sub>16</sub>-arylalkenyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkenyl is C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>8</sub>-C<sub>16</sub>-arylalkinyl, where aryl is C<sub>6</sub>-C<sub>10</sub>-aryl and alkinyl is C<sub>2</sub>-C<sub>6</sub>-alkinyl.

16. (Previously Presented) A composition according to claim 10, wherein in the compound, R<sub>3</sub> is hydrogen or alkyl.

17. (Previously Presented) A composition according to claim 13, wherein in the compound, R<sub>2</sub> is aralkyl.

18. (Currently Amended) A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier substance and (ii) a compound and/or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

14 $\beta$ -[(2-chlorobenzyl)oxy]-17-(cyclopropylmethyl)-4,5 $\alpha$ -epoxy-3-hydroxymorphinan-6-one,  
~~14 $\beta$ -benzyloxy-17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxymorphinan-6-one, 17-~~  
cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -[(3-methylbutyl)oxy]morphinan-6-one, 14 $\beta$ -[(3-

chlorobenzyl)oxy]-4,5 $\alpha$ -epoxy-17-methyl-3-[(prop-2-inyl)oxy]morphinan-6-one, 5 $\beta$ -benzyl-14-methoxycodeinone (= 5-benzyl-7,8-didehydro-4,5 $\alpha$ -epoxy-3,14 $\beta$ -dimethoxy-17-methylmorphinan-6-one), 5 $\beta$ -benzyl-4,5 $\alpha$ -epoxy-3,14 $\beta$ -dimethoxy-17-methylmorphinan-6-one, 5 $\beta$ -benzyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -methoxy-17-methylmorphinan-6-one, 14 $\beta$ -benzyloxy-4-hydroxy-3-methoxy-17-methylmorphinan-6-one, 14 $\beta$ -benzyloxy-3,4-dimethoxy-17-methylmorphinan-6-one, 14 $\beta$ -ethoxy-4-hydroxy-3-methoxy-5 $\beta$ ,17-dimethylmorphinan-6-one, 14 $\beta$ -benzyloxy-3,4-dimethoxy-5 $\beta$ ,17-dimethylmorphinan-6-one, (17R)-17-allyl-4,5 $\alpha$ -epoxy-14 $\beta$ -ethoxy-3-hydroxy-17-methyl-6-oxomorphinan-iodide, (17R)-17-allyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -methoxy-17-methyl-6-oxomorphinan-iodide, (17S)-17-allyl-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -methoxy-17-methyl-6-oxomorphinan-iodide, 4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -methoxy-17,17-dimethyl-6-oxomorphinan-iodide, (17R)-14 $\beta$ -[(4-chlorobenzyl)oxy]-17-cyclopropylmethyl-4,5 $\alpha$ -epoxy-3-hydroxy-17-methyl-6-oxomorphinan-iodide and 17(R)-4,5 $\alpha$ -epoxy-3-hydroxy-14 $\beta$ -methoxy-17-methyl-6-oxo-17-(2-phenylethyl)morphinan-iodide.